Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...